BrightSpring Health’s Onco360 Becomes National Pharmacy Partner for Voydeya Treatment
Onco360, a specialty pharmacy focused on oncology and owned by BrightSpring Health Services, has been selected by Alexion Pharmaceuticals as the national pharmacy partner to handle the distribution of Voydeya (Danicopan). Voydeya is a first-in-class, oral Factor D inhibitor, developed to treat patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) experiencing extravascular hemolysis (EVH). The announcement marks an essential milestone for both companies and promises to bring renewed hope for patients struggling with this rare, life-threatening blood disease.
BrightSpring Health Services, publicly-traded on NASDAQ under the ticker BTSG, has a keen focus on providing comprehensive health services across a broad range of clinical and non-clinical specialties. Now, through its oncology-focused pharmacy, Onco360, BrightSpring will play a pivotal role in ensuring the smooth nationwide distribution and accessibility of Voydeya for patients in need.
Voydeya stands as a first-in-class medication and represents a crucial advancement in treatment options for patients with PNH, a rare, life-threatening blood disease. The disease affects a minuscule portion of the population, causing red blood cells to break apart, leading to anemia, blood clots, and impaired quality of life. However, the most serious complication, EVH, has proven to be the hardest to manage, until now.
With the approval and release of Voydeya, patients experiencing EVH, which causes red blood cells to lyse, or burst apart, can look forward to more comprehensive and practical treatment options. It’s worth noting that Voydeya targets the underlying cause of PNH by inhibiting Factor D, a part of the body’s complement system contributing to red blood cells’ destruction in PNH patients.
The partnership between Alexion Pharmaceuticals, the creators of Voydeya, and Onco360, under the BrightSpring Health Services banner, aims to ensure patients have broad access to this groundbreaking medication. By leveraging Onco360’s specialty pharmacy services, patients across the nation will receive expert assistance in managing their medication journey, underscoring BrightSpring’s commitment to enhancing the quality of life for those dealing with severe health issues.
The alliance brings to the fore BrightSpring’s mission to be at the forefront of clinically-focused services, optimizing patient outcomes, and showcasing their dedication to making a genuine difference in the healthcare landscape.
While the partnership establishes a significant milestone for Onco360 and BrightSpring Health Services, it marks an equally weighty landmark moment for Alexion, who will be hoping that Voydeya can play a transformative role in improving PNH patient outcomes on a national scale.
Comments